Mobilization of hematopoietic stem cells

Blood Reviews

Volumn 14, Issue 4, 2000, Pages 205-218

  Fu, S ^a   Liesveld, J ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; PACLITAXEL;

ARTICLE; BLOOD; BLOOD DISEASE; BONE MARROW; BONE MARROW TRANSPLANTATION; BREAST CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL RESEARCH; HEMATOPOIETIC STEM CELL; HUMAN; LUNG CANCER; LYMPHOMA; MOBILIZATION; MODEL; PATIENT CARE; PRIORITY JOURNAL; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 0034492315     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2000.0138     Document Type: Article

References (135)

1. The use of mobilized peripheral blood stem cells from normal donors for allografting
2. Peripheral blood stem cell mobilization for high-dose chemotherapy
3. Innovations in allogeneic stem-cell transplantation
4. The feasibility of peripheral blood stem cell collection for autograft following failure in bone marrow aspiration
5. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells
6. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
7. Autologous stem cell transplantation in chronic myeloid leukaemia using Philadelphia chromosome negative blood progenitors mobilised with hydroxyurea and G-CSF
8. (R)evolutionary considerations in hematopoietic development
9. Paradigm shifts in stem cell biology
10. Advances in leukocyte differential and peripheral blood stem cell enumeration
11. Quiescence, cycling and turnover in the primitive hematopoietic stem cell compartment
12. Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin's lymphoma (NHL): Application in clinical practice
13. A neutralizing anti-TGF-beta1 antibody promotes proliferation of CD34+Thy-1+ peripheral blood progenitors and increases the number of transduced progenitors
14. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue
15. Phenotypic molecular, and functional characterization of human peripheral blood CD+/Thyl+ cells
16. KDR receptor: A key marker defining hematopoietic stem cells
17. Dye effiux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species
18. Cycling status of CD34+ cells mobilized into peripheral blood of healthy donors by recombinant human granulocyte colony-stimulating factor
19. Allogeneic hematopoietic stem cells from sources other than bone marrow: Biological and technical aspects
20. Stem cell mobilisation in lymphoproliferative diseases
21. Blood stem cell procurement: Donor safety issues
22. Effect of CD34(+) cell dose on resource utilization in patients after high-dose chemotherapy with peripheral-blood stem-cell support
23. Collection of peripheral blood progenitor cells (PBPC) based on a rising WBC and platelet count significantly increases the number of CD34+ cells
24. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation
25. Using at least 5xl0(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation
26. RE The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients
27. The role of the Sysmex SE9000 immature myeloid index and Sysmex R2000 reticulocyte parameters in optimizing the timing of peripheral blood stem cell harvesting in patients with lymphoma and myeloma
28. A comparative study of a new, fully automated procedure and the standard mononuclear cell program using the Cobe Spectra for peripheral blood stem cell collection
29. Isolation of CD34+ cells from blood stem cell components using the Baxter Isolex system
30. Repeated peripheral stem cell mobilization in healthy donors: Time- dependent changes in mobilization efficiency
31. First and second apheresis in patients with multiple myeloma: No differences in tumor load and hematopoietic stem cell yield
32. Kinetics of peripheral blood stem cell harvests during a single apheresis
33. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy
34. Concomitant mobilization of plasma cells and hematopoietic progenitors into progenitors into peripheral blood of multiple myeloma patients: Positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells
35. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC)
36. Docetaxel-induced mobilization of hematopoietic stem cells in a murine model: Kinetics, dose titration, and toxicity
37. Cyclophosphamide and paclitaxel as initial or salvage regimen for the mobilization of peripheral blood progenitor cells
38. Mobilization of peripheral blood progenitor cells with paclitaxel-based chemotherapy
39. Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization: Comparative studies in a murine model
40. Blood stem cell collection using chemotherapy with or without systematic G-CSF: Experience in 52 patients with multiple myeloma
41. The utilization of cytokines in stem cell mobilization strategies
42. Phenotype and engraftment potential of cytokine-mobilized peripheral blood mononuclear cells
43. The role of granulocyte colony-stimulating factor in hematopoietic stem cell transplantation
44. Mobilization/harvest and transplantation with blood stem cells, manipulated or unmanipulated
45. Granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in betathalassemia patients: Kinetics of mobilization and composition of apheresis product
46. Stem cell mobilization with G-CSF alone in breast cancer patients: Higher progenitor cell yield by delivering divided doses (2 × 5 microg/kg) compared to a single dose (1 × 10 microg/kg)
47. Comparison of lenograstim vs filgrastim administration following chemotherapy for peripheral blood stem cell (PBSC) collection: A retrospective study of 126 patients
48. Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor
49. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotherapeutic agent, associated with rhG-CSF
50. Comparison of the distribution of progenitor cells in G-CSF-mobilized peripheral blood and steady-state bone marrow after counterflow centrifugal elutriation
51. Administration of recombinant human granulocyte colony- stimulating factor to normal donors: Results of the Spanish National Donor Registry
52. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: A randomized, controlled trial
53. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: Enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor
54. Use of stem cell factor to mobilize hematopoietic progenitors
55. Stem cell factor leads to reduced blood processing during apheresis or the use of whole blood aliquots to support dose-intensive chemotherapy
56. HG Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients
57. Mobilizing peripheral blood stem cells with high-dose G-CSF alone is as effective as with Dexa-BEAM plus G-CSF in lymphoma patients
58. Selective in vivo mobilization with granulocyte macrophage colony-stimulating factor (GM-CSF)/granulocyte-CSF as compared to G-CSF alone of dendritic cell progenitors from peripheral blood progenitor cells in patients with advanced breast cancer undergoing autologous transplantation
59. G-CSF versus GM-CSF for stimulation of peripheral blood progenitor cells (PBPC) and leukocytes in healthy volunteers: Comparison of efficacy and tolerability
60. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripehral blood stem cells: Effects on hematopoietic recovery after high-dose chemotherapy
61. Randomized comparison of progenitor-cell mobilization using chemotherapy, stem-cell factor, and filgrastim or chemotherapy plus filgrastim alone in patients with ovarian cancer
62. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor
63. Optimization of peripheral blood stem cell mobilization
64. Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization
65. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma
66. Nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mouse as a model system to study the engraftment and mobilization of human peripheral blood stem cells
67. Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis
68. A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells
69. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer
70. Mini-ICE regimen as mobilization therapy for chronic myelogenous leukemia patients at diagnosis
71. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease
72. Stem cell mobilization in resistant or relapsed lymphoma: Superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide
73. Dose-intense paclitaxel, etoposide and cyclophosphamide: A safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer
74. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
75. Mobilization of peripheral blood stem cells in children using G-CSF after carboplatin containing myelosuppressive chemotherapy
76. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens
77. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: A retrospective analysis of a 10-year single institution experience
78. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients
79. Stem cell function and engraftment is not affectd by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma
80. Enhancement of the anti-tumor activity of a peripheral blood progenitor cell graft by mobilization with interleukin 2 plus granulocyte colony-stimulating factor in patients with advanced breast cancer
81. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma
82. Management strategies for the hard-to-mobilize patient
83. Factors that influence the collection and engraftment of allogeneic peripheral-blood stem cells in patients with hematologic malignancies
84. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization
85. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma
86. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: An analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma
87. Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied
88. Reduced bone marrow stem cell pool and progenitor mobilisation in multiple myeloma after melphalan treatment
89. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas espeeially when mobilized within 6 months of previous chemotherapy
90. Continuous infusion of macrophage inflammatory protein MIP-1 alpha enhances leucocyte recovery and haemopoietic progenitor cell mobilization after cyclophosphamide
91. Efficient peripheral blood stem cell mobilization with low-dose G-CSF (50 microg/m2) after salvage chemotherapy for lymphoma
92. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF
93. The administration of 10 microg/kg granulocyte colony-stimulating factor (G-CSF) alone results in a successful peripheral blood stem cell collection when previous mobilization with chemotherapy and hematopoietic growth factor failed
94. A Successful peripheral blood stem cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization
95. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients
96. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients- Results of a phase I/II trial
97. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients
98. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential
99. Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits
100. Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer
101. The biology and clinical uses of blood stem cells
102. Difference between expression of adhesion molecules on CD34+ cells from bone marrow and G-CSF-stimulated peripheral blood
103. Extensive phenotypic analysis of CD34 subsets in successive collections of mobilized peripheral blood progenitors
104. Impact of stem cell on hematopoietic recovery in autologous blood stem cell recipients
105. Modulation of VLA4 and L-selectin expression on normal CD34+ cells during mobilization with G-CSF
106. Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factor
107. GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression
108. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: A matched pairs analysis of 78 patients
109. Mechanisms of granulocyte colony stimulating factor-induced hematopoietic progenitor cell mobilization
110. RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase negative and noncycling irrespective of CD33 or CD13 coexpression
111. Chemokine SDF-1 enhances circulating CD34(+) cell proliferation in synergy with cytokines: Possible role in progenitor survival
112. The granulocyte colony-stimulating factor receptor is required for the mobilization of murine hematopoietic progenitors into peripheral blood by cyclophosphamide or interleukin 8 but not flt-3 ligand
113. Prevention of interleukin 8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by antibodies to the metalloproteinase gelatinase B
114. The role of metalloproteinases and adhesion molecules in interleukin 8-induced stem cell mobilization
115. Mechanisms of stem/progenitor cell mobilization: The anti-VLA4 paradigm
116. Anti-VLA4/VCAMI induced mobilization requires cooperative signaling through the kit receptor/mkit ligand
117. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane
118. The Jak-Stat pathway in normal and perturbed hematopoiesis
119. Cytophosphamide/granulocyte colony stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization
120. The unexpected G0/G1 cell cycle status of mobilized hematopoietic stem cells from peripheral blood
121. High-dose granulocyte-colony stimulating factor (G-CSF) in vitro induces the growth of high proliferative potential colony forming cells (HPP-CFC) in patients undergoing blood stem cell mobilization
122. Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma
123. CD95 (APO1/FAS)-mediated apoptosis in cytokine-activated hematopoietic cells
124. G-CSF-mobilized CD34 peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34 cells: Role of G-CSF as survival factor
125. Homing and mobilization in the stem cell niche
126. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting
127. Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor
128. Peripheral blood stem cell mobilization and apheresis: Analysis of adverse events in 94 normal donors
129. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone
130. Analysis of CD34 populations in mobilised peripheral blood stem cell harvests and in bone marrow by fluorescent in situ hybridisation for the bcr/abl gene fusion in patients with chronic granulocytic leukaemia
131. Circulating primitive stem cells in paroxysmal nocturnal hemoglobinuria (PNH) are predominantly normal in phenotype but granulocyte colony-stimulating factor treatment mobilizes mainly PNH stem cells
132. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
133. Anaphylactoid reaction to granulocyte colony-stimulating factor used in mobilization of peripheral blood stem cell
134. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease
135. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: Enhanced CD34+ cell collections are not necessarily cost-effective